Nxc-201

Phase 3

NNexcella Inc.

Nxc-201 is one of 5 therapeutic programs targeting Light Chain (AL) Amyloidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Light Chain (AL) AmyloidosisNot yet recruiting

Light Chain (AL) AmyloidosisPhase 3

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Light Chain (AL) Amyloidosis

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Etentamig

AbbVie

Phase 3

1 3

Venclexta

AbbVie

Phase 2

1 4

Nxc-201

NNexcella Inc.

Phase 3

1 5

First-Line Dara-Borcyd Treatment

PPeking University First Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

Phase 3Not yet recruiting

Light Chain (AL) Amyloidosis

NCT07709715

Clinical

Trials by Indication[1]

Light Chain (AL) Amyloidosis1 trial

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis [NEXICART-3]

Not yet recruiting·NNexcella Inc.·Phase 3·NCT07709715·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nxc-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nxc-201. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Nexcella Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: NNexcella Inc.

Nxc-201

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Light Chain (AL) Amyloidosis1 trial

References

Drug Info

Quick Facts

Related News